An assay that makes use of leukemia stem cells (LSCs) to evaluate measurable residual illness (MRD) outperforms conventional strategies in sufferers with acute myeloid leukemia (AML), based on a research revealed on-line Aug. 23 in Bone Marrow Transplantation.
Si-Qi Li, from the Peking College Folks’s Hospital in Beijing, and colleagues assessed the power of the LSC-based technique and the normal multiparameter circulate cytometry (MFC) assay to foretell leukemia relapse after long-term follow-up. The evaluation included 360 sufferers with AML who acquired allografts between July 2018 and November 2019.
The researchers discovered that sufferers with constructive MRD primarily based on CD34+CD38−cocktail+ LSCs (≥0.004%) had a better five-year cumulative incidence of relapse (CIR; 49.7 versus 8.5%), inferior leukemia-free survival (LFS; 48.2 versus 84.4%), and inferior total survival (OS; 59.7 versus 82.8%) versus sufferers with out CD34+CD38−cocktail+ LSCs (
Sufferers with detectable conventional MFC-MRD additionally had a better CIR than sufferers with out MRD (45.8 versus 10.9%), leading to decreased LFS (54.2 versus 81.9%) and decreased OS (56.0 versus 85.9%). The LSC-based MRD assay had good efficiency, with excessive sensitivity (52.4 versus 33.3%), a excessive C-index (0.72 versus 0.65), and excessive Youden index (0.44 versus. 0.27), in contrast with conventional MFC-MRD. The median time from LSC positivity to relapse was longer in contrast with conventional MRD positivity to relapse (144 versus 65 days).
“The results reported by other researchers and from our long-term follow-up study provide further evidence that the LSC-based MRD assay should be recommended for relapse prediction in patients with AML,” the authors write.
Extra info:
Si-Qi Li et al, Leukemia stem cells for relapse prediction in AML sufferers receiving allografts: long-term follow-up of a potential research, Bone Marrow Transplantation (2025). DOI: 10.1038/s41409-025-02699-8
© 2025 HealthDay. All rights reserved.
Quotation:
Leukemia stem cell-based technique aids relapse prediction in acute myeloid leukemia (2025, August 29)
retrieved 29 August 2025
from https://medicalxpress.com/information/2025-08-leukemia-stem-cell-based-method.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
